Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C, Chronic | 4 | 2013 | 356 | 0.820 |
Why?
|
| Interferons | 3 | 2013 | 138 | 0.740 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2026 | 148 | 0.710 |
Why?
|
| Antiviral Agents | 5 | 2021 | 805 | 0.660 |
Why?
|
| Ribavirin | 3 | 2010 | 85 | 0.650 |
Why?
|
| Kupffer Cells | 1 | 2019 | 20 | 0.580 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2019 | 62 | 0.550 |
Why?
|
| Calcineurin Inhibitors | 1 | 2017 | 25 | 0.500 |
Why?
|
| Everolimus | 1 | 2017 | 49 | 0.490 |
Why?
|
| Liver Transplantation | 5 | 2017 | 1134 | 0.490 |
Why?
|
| Graft Survival | 1 | 2017 | 459 | 0.430 |
Why?
|
| Hepatitis B | 2 | 2021 | 170 | 0.420 |
Why?
|
| Liver | 2 | 2019 | 1780 | 0.420 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2014 | 975 | 0.380 |
Why?
|
| Graft Rejection | 1 | 2017 | 540 | 0.380 |
Why?
|
| Kidney Diseases | 1 | 2017 | 474 | 0.370 |
Why?
|
| Retinal Diseases | 1 | 2013 | 142 | 0.350 |
Why?
|
| Lypressin | 1 | 2010 | 17 | 0.310 |
Why?
|
| Hepatorenal Syndrome | 1 | 2010 | 31 | 0.300 |
Why?
|
| Vasoconstrictor Agents | 1 | 2010 | 136 | 0.290 |
Why?
|
| Hepatitis B virus | 1 | 2009 | 133 | 0.290 |
Why?
|
| Enterocolitis, Neutropenic | 1 | 2007 | 2 | 0.270 |
Why?
|
| Fibrosis | 1 | 2009 | 421 | 0.270 |
Why?
|
| Liver Cirrhosis | 4 | 2020 | 901 | 0.260 |
Why?
|
| Bariatric Surgery | 1 | 2008 | 153 | 0.240 |
Why?
|
| Immunosuppressive Agents | 3 | 2021 | 652 | 0.240 |
Why?
|
| Polyethylene Glycols | 1 | 2007 | 232 | 0.240 |
Why?
|
| Fatty Liver | 1 | 2008 | 221 | 0.240 |
Why?
|
| Interferon-alpha | 1 | 2007 | 238 | 0.240 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 1366 | 0.200 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2026 | 204 | 0.190 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 33 | 0.160 |
Why?
|
| Hepatitis C | 2 | 2017 | 381 | 0.150 |
Why?
|
| Skin Diseases | 1 | 2021 | 141 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 1262 | 0.140 |
Why?
|
| Lip Neoplasms | 1 | 2017 | 4 | 0.130 |
Why?
|
| Ethanol | 1 | 2019 | 167 | 0.130 |
Why?
|
| Humans | 18 | 2026 | 130459 | 0.130 |
Why?
|
| Glomerular Filtration Rate | 2 | 2017 | 566 | 0.120 |
Why?
|
| Liver Failure | 1 | 2017 | 98 | 0.120 |
Why?
|
| Kidney Function Tests | 1 | 2017 | 135 | 0.120 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 127 | 0.120 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 1165 | 0.120 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 312 | 0.110 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2020 | 400 | 0.110 |
Why?
|
| Evidence-Based Medicine | 2 | 2021 | 643 | 0.110 |
Why?
|
| Sirolimus | 1 | 2017 | 230 | 0.110 |
Why?
|
| Models, Statistical | 1 | 2017 | 483 | 0.110 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 1211 | 0.110 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2014 | 23 | 0.100 |
Why?
|
| Niacinamide | 1 | 2014 | 31 | 0.100 |
Why?
|
| Phenylurea Compounds | 1 | 2014 | 57 | 0.100 |
Why?
|
| Metabolomics | 1 | 2017 | 500 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 567 | 0.100 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 3038 | 0.090 |
Why?
|
| Length of Stay | 1 | 2017 | 1412 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2014 | 12840 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 384 | 0.090 |
Why?
|
| Jejunal Neoplasms | 1 | 1991 | 5 | 0.080 |
Why?
|
| Tuberculosis, Gastrointestinal | 1 | 1991 | 6 | 0.080 |
Why?
|
| Jejunal Diseases | 1 | 1991 | 11 | 0.080 |
Why?
|
| Time Factors | 3 | 2010 | 6168 | 0.080 |
Why?
|
| Kidney | 1 | 2017 | 1280 | 0.080 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2019 | 830 | 0.080 |
Why?
|
| Prognosis | 2 | 2017 | 4865 | 0.080 |
Why?
|
| Catheter Ablation | 1 | 2014 | 322 | 0.080 |
Why?
|
| Melanoma | 1 | 2017 | 927 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2010 | 3683 | 0.080 |
Why?
|
| Middle Aged | 6 | 2020 | 28406 | 0.080 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2009 | 60 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 1123 | 0.070 |
Why?
|
| Alanine Transaminase | 1 | 2009 | 153 | 0.070 |
Why?
|
| Hospitalization | 1 | 2017 | 1942 | 0.070 |
Why?
|
| DNA, Viral | 1 | 2009 | 447 | 0.070 |
Why?
|
| Biomarkers | 3 | 2020 | 3367 | 0.070 |
Why?
|
| Filgrastim | 1 | 2007 | 13 | 0.070 |
Why?
|
| Creatinine | 1 | 2010 | 398 | 0.070 |
Why?
|
| Dipeptidases | 1 | 2007 | 15 | 0.070 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2007 | 91 | 0.060 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 1545 | 0.060 |
Why?
|
| Risk Factors | 2 | 2013 | 11004 | 0.060 |
Why?
|
| Male | 8 | 2020 | 64567 | 0.060 |
Why?
|
| Recurrence | 1 | 2010 | 1482 | 0.060 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2007 | 324 | 0.060 |
Why?
|
| Incidence | 1 | 2013 | 3335 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 2007 | 1319 | 0.050 |
Why?
|
| Adult | 6 | 2020 | 31094 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 1991 | 970 | 0.050 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2002 | 51 | 0.050 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2002 | 88 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2008 | 1701 | 0.040 |
Why?
|
| Female | 7 | 2020 | 70497 | 0.040 |
Why?
|
| Aged | 4 | 2017 | 20884 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2014 | 4664 | 0.040 |
Why?
|
| Liver Failure, Acute | 1 | 2002 | 94 | 0.040 |
Why?
|
| Dermatologists | 1 | 2021 | 5 | 0.040 |
Why?
|
| Biopsy | 2 | 2017 | 1229 | 0.040 |
Why?
|
| Hepatitis B Vaccines | 1 | 2021 | 49 | 0.040 |
Why?
|
| Immunization, Secondary | 1 | 2021 | 118 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2007 | 2060 | 0.040 |
Why?
|
| Young Adult | 2 | 2017 | 10032 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2017 | 97 | 0.030 |
Why?
|
| Mycophenolic Acid | 1 | 2017 | 54 | 0.030 |
Why?
|
| Steroids | 1 | 2017 | 168 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2007 | 2579 | 0.030 |
Why?
|
| Algorithms | 1 | 2021 | 1669 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2017 | 524 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2896 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 1282 | 0.020 |
Why?
|
| Disease Progression | 1 | 2017 | 2192 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2020 | 17625 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 1991 | 221 | 0.020 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 1991 | 228 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 5180 | 0.020 |
Why?
|
| Ligation | 1 | 2007 | 134 | 0.020 |
Why?
|
| Bile Ducts | 1 | 2007 | 52 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2007 | 297 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 421 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2007 | 760 | 0.010 |
Why?
|
| Rats | 1 | 2007 | 3371 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 20864 | 0.010 |
Why?
|
| Animals | 1 | 2007 | 33713 | 0.000 |
Why?
|